5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, neoplasm, stomach disorderActive, not recruitingPhase 32026-09-28NCT03653507
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderMuscle-invasive Bladder CancerRecruitingPhase 22026-09-24NCT07475806
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerNeoplasms by Histologic Type, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasmRecruitingPhase 32026-09-24NCT06901531
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 22026-09-11NCT02960022
A Study of Zolbetuximab (IMAB362) in Adults With Gastric CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorderActive, not recruitingPhase 22026-08-31NCT03505320